Perspective Therapeutics' (CATX) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX - Free Report) in a research report released on Monday morning, MarketBeat Ratings reports. Wedbush currently has a $11.00 target price on the stock.

Other analysts also recently issued reports about the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Truist Financial lowered their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics presently has an average rating of "Buy" and an average target price of $12.56.

Perspective Therapeutics Trading Down 5.0%

Shares of CATX traded down $0.19 on Monday, reaching $3.62. The company's stock had a trading volume of 1,133,535 shares, compared to its average volume of 1,090,843. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $16.55. The firm has a fifty day moving average of $2.75 and a 200-day moving average of $2.85.

Insider Activity

In other news, CFO Juan Graham acquired 33,333 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.25 per share, with a total value of $74,999.25. Following the acquisition, the chief financial officer now owns 35,354 shares in the company, valued at $79,546.50. The trade was a 1,649.33% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert F. Williamson III acquired 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the purchase, the director now directly owns 70,837 shares in the company, valued at $160,799.99. This trade represents a 45.62% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock valued at $256,344 in the last three months. Company insiders own 3.72% of the company's stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the 4th quarter worth approximately $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the fourth quarter worth $34,000. National Bank of Canada FI grew its position in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Perspective Therapeutics during the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.